Review

Oral immunotherapy: The answer to peanut allergy?

Rachel M. Whitsel, APRN, Jaclyn A. Bjelac, MD, Ahila Subramanian, MD, Alice E. W. Hoyt, MD and Sandra J. Hong, MD
Cleveland Clinic Journal of Medicine February 2021, 88 (2) 104-109; DOI: https://doi.org/10.3949/ccjm.88a.20130

Article Figures & Data

Tables

  • TABLE 1

    Protocol for the peanut-derived oral immunotherapy agent

    PhaseDurationDosage
    Dose-escalationSingle day5 levels: 0.5, 1, 1.5, 3, and 6 mg; increasing doses every 20–30 minutes
    Up-dosingMonths11 levels: 3, 6, 12, 20, 40, 80, 120, 160, 200, 240, and 300 mg daily; increasing doses at visits every 2 weeks
    MaintenanceMonths to years300 mg daily

    • Adapted from information in reference 15.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects